Lipoprotein-associated phospholipase A2 levels, endothelial dysfunction and arterial stiffness in patients with stable coronary artery disease

Mourouzis, Konstantinos; Siasos, Gerasimos; Oikonomou, Evangelos; Zaromitidou, Marina; Tsigkou, Vicky; Antonopoulos, Alexis; Bletsa, Evanthia; Stampouloglou, Panagiota; Vlasis, Konstantinos; Vavuranakis, Manolis; Tousoulis, Dimitris

doi:10.1186/s12944-021-01438-4

Lipids in Health and Disease

Table 2 Multiple linear regression analysis for the association of FMD and AIx with several variables

From: Lipoprotein-associated phospholipase A2 levels, endothelial dysfunction and arterial stiffness in patients with stable coronary artery disease

Variables	Regression analysis for the association of FMD (dependent variable) with Lp-PLA2 after adjustment for multiple classical risk factors for CAD			Regression analysis for the association of AIx (dependent variable) with Lp-PLA2 after adjustment for multiple classical risk factors for CAD
Variables	b coefficient	95% CI	P value	b coefficient	95% CI	p-value
Gender	− 0.30	− 1.48 – 0.87	0.61	−7.16	− 11.30 – 3.03	< 0.001
Age (years)	− 0.01	− 0.04 – 0.03	0.69	0.22	0.11 – − 0.34	< 0.001
Duration of CAD (months)	0.01	− 0.01 – 0.02	0.59	0.01	−0.05 – 0.07	0.68
Arterial hypertension	0.76	−0.18 – 1.69	0.11	−0.94	−4.12 – 2.25	0.56
Diabetes mellitus	−0.25	−2.07 – 1.57	0.79	5.89	0.01–11.78	0.05
Hyperlipidemia	−0.20	−1.10 – 0.70	0.66	1.43	−1.74 – 4.59	0.37
Smoking history	−0.18	−0.64 - 0.28	0.44	1.66	0.07–3.25	0.04
Family history for CAD	0.74	−0.07 – 1.55	0.07	−1.26	−4.12 – 1.60	0.39
Previous MI	0.08	−0.60 – 0.77	0.81	0.07	−2.40 – 2.53	0.96
Statins	−1.12	−2.32 – 0.08	0.07	−1.98	−5.96 – 1.99	0.33
Antidiabetic agents	−0.01	−1.80 – 1.78	0.99	−5.49	−11.31 – 0.33	0.06
ACEi/ARBs	−0.18	−0.94 – 0.57	0.63	1.61	−1.13 – 4.35	0.25
β-blockers	0.04	−0.72 – 0.81	0.91	0.29	−2.46 – 3.04	0.83
Cholesterol (mg/dL)	0.01	−0.001 – 0.02	0.55	0.01	−0.04 – 0.06	0.66
LDL (mg/dL)	−0.01	−0.03 – 0.01	0.19	0.02	−0.04 – 0.08	0.50
Glucose (mg/dL)	0.01	−0.01 – 0.01	0.73	−0.01	−0.04 – 0,02	0.54
Lp-PLA2 > 138 μg/L	− 0.45	−0.79 - -0.11	0.01	1.81	0.57 - 3.05	< 0.001

For categorical variables, reference category was set the absence of male gender, diabetes mellitus, hyperlipidemia, smoking history, arterial hypertension, family history for CAD, previous myocardial infarction, statin therapy, treatment with ACEi/ARBs, antidiabetic agents or with β-blockers and Lp-PLA2 < 101 μg/L (1st tertile). AIx Augmentation Index, FMD Flow-mediated dilatation, CAD Coronary artery disease, Lp-PLA2 Lipoprotein-associated phospholipase A2, ACEi Angiotensin converting enzyme inhibitors, ARBs Angiotensin II receptor blockers, MI Myocardial infarction

Back to article page

ISSN: 1476-511X

Contact us

General enquiries: journalsubmissions@springernature.com